Drug Profile
Research programme: cancer therapeutics - BRIM Biotechnology/Compliment Corporation
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator BRIM Biotechnology; Compliment Corporation
- Class Recombinant proteins
- Mechanism of Action CD46 antigen inhibitors; Desmoglein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Cancer in Taiwan (Parenteral)
- 28 Oct 2018 No recent reports of development identified for research development in Cancer in USA (Parenteral)